Noden Drug Patent Portfolio
Noden owns 1 orange book drug protected by 4 US patents Given below is the list of Noden's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8618172 | Galenical formulations of organic compounds | 13 Jul, 2028 | Active |
| US9023893 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | 03 Mar, 2022 | Expired |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | 21 Jan, 2019 | Expired |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | 21 Jul, 2018 | Expired |
Latest Legal Activities on Noden's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Noden.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 12 Jun, 2023 | US9023893 |
|
Maintenance Fee Reminder Mailed
Critical
| 26 Dec, 2022 | US9023893 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jun, 2021 | US8618172 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2018 | US9023893 |
|
Recordation of Patent Grant Mailed
Critical
| 05 May, 2015 | US9023893 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 May, 2015 | US9023893 |
|
Email Notification
Critical
| 16 Apr, 2015 | US9023893 |
|
Issue Notification Mailed
Critical
| 15 Apr, 2015 | US9023893 |
| Post Issue Communication - Certificate of Correction | 09 Apr, 2015 | US8618172 |
| Dispatch to FDC | 03 Apr, 2015 | US9023893 |
|
Application Is Considered Ready for Issue
Critical
| 03 Apr, 2015 | US9023893 |
|
Issue Fee Payment Received
Critical
| 02 Apr, 2015 | US9023893 |
|
Issue Fee Payment Verified
Critical
| 02 Apr, 2015 | US9023893 |
|
Email Notification
Critical
| 06 Feb, 2015 | US8618172 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 02 Feb, 2015 | US8618172 |
Noden Drug Patents' Oppositions Filed in EPO
Noden drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 04, 2009, by Teva Pharmaceuticals Industries Ltd.. This opposition was filed on patent number EP05015603A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08002401A | Apr, 2014 | STADA Arzneimittel AG | Revoked |
| EP05015603A | Mar, 2009 | Ratiopharm GmbH | Revoked |
| EP05015603A | Feb, 2009 | TEVA PHARMACEUTICALS INDUSTRIES LTD. | Revoked |
Noden's Family Patents
Noden Drug List
Given below is the complete list of Noden's drugs and the patents protecting them.
1. Tekturna Hct
Tekturna Hct is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8618172 | Galenical formulations of organic compounds |
13 Jul, 2028
(2 years from now)
| Active |
| US9023893 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
03 Mar, 2022
(3 years ago)
| Expired |
| US5559111
(Pediatric)
| δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jan, 2019
(7 years ago)
| Expired |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jul, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekturna Hct's drug page